Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934873 | 1.00 | CCKBR (1.00) | CCKBRTP53CYP1A2CYP3A4MAPT | |
| SCHEMBL9203429 | 0.80 | CCKBR (0.80) | CCKBRTP53CYP1A2CYP3A4MAPT | |
| SCHEMBL9209152 | 0.77 | CCKBR (0.76) | CCKBR | |
| SCHEMBL16620509 | 0.72 | HIF1A (0.60) | CCKBRTP53CYP1A2CYP3A4MAPT | |
| SCHEMBL8502010 | 0.71 | SMN1; SMN2 (0.56) | CCKBR | |
| SCHEMBL8503645 | 0.71 | SMN1; SMN2 (0.56) | CCKBR | |
| SCHEMBL6308294 | 0.68 | CCKBR (0.63) | CCKBR | |
| SCHEMBL9209580 | 0.68 | CCKBR (0.60) | CCKBRTP53CYP1A2CYP3A4MAPT | |
| SCHEMBL9203141 | 0.67 | NPC1 (0.64) | CCKBRMAPT | |
| SCHEMBL31525981 | 0.66 | MAPT (0.49) | CCKBRTP53CYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0729752-A2 | Central cholecystokinin antagonists having pharmaceutical activity | MERCK SHARP & DOHME LTD. (GB) | 1996-09-04 | — | — | EP | claimed |
| WO-1993012791-A1 | CENTRAL CHOLECYSTOKININ ANTAGONISTS HAVING PHARMACEUTICAL ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 1993-07-08 | — | — | WO | claimed |
| EP-0729752-A2 | Central cholecystokinin antagonists having pharmaceutical activity | MERCK SHARP & DOHME LTD. (GB) | 1996-09-04 | — | — | EP | disclosed |
| EP-0475755-B1 | 3-Aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof | LILLY CO ELI (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1993012791-A1 | CENTRAL CHOLECYSTOKININ ANTAGONISTS HAVING PHARMACEUTICAL ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 1993-07-08 | — | — | WO | disclosed |
| US-5196427-A | Gastrointestinal and central nervous system disorders; hormone inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0475755-A1 | 3-Aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof | ELI LILLY AND COMPANY (US) | 1992-03-18 | — | — | EP | disclosed |
| US-5075313-A | For bindign to cholecystokinin receptors | ELI LILLY AND COMPANY (US) | 1991-12-24 | — | — | US | disclosed |